Cagrilintide vs Semaglutide

Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination

A once-weekly long-acting amylin analogue in late-stage development. Showing impressive weight loss (~15%) in trials, especially when combined with semaglutide (CagriSema).

Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.

Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It is among the most prescribed and searched compounds in the weight loss space. Compounding pharmacies have produced semaglutide formulations under 503A and 503B frameworks, with significant provider interest across the telehealth and functional medicine space. Its mechanism involves both peripheral and central appetite suppression.